The global biopharmaceutical contract manufacturing market is on a remarkable growth trajectory, projected to reach a valuation of USD 10.7 billion in 2024. Recent market forecasts indicate an impressive compound annual growth rate (CAGR) of 8.8%, potentially culminating in a market size of USD 25.1 billion by 2034.
This robust expansion is largely driven by the increasing complexity of biologics—intricate molecules that require specialized expertise for effective production. In response to the growing demands of the biopharmaceutical landscape, many pharmaceutical companies, particularly small and mid-sized biopharmaceutical firms, are opting to outsource their manufacturing processes to contract manufacturing organizations (CMOs). This trend stems from a lack of in-house resources and the specialized know-how required for advanced biologics production.
As the global biopharmaceutical market continues to evolve, the need for efficient and innovative manufacturing processes is becoming increasingly critical. A significant factor propelling this growth is the rising adoption of cell and gene therapies. These advanced therapies necessitate specialized manufacturing facilities and technical expertise, positioning CMOs as key players in the biopharmaceutical supply chain.
However, this expanding market landscape is not without challenges. The risk of intellectual property theft poses a serious concern for industry stakeholders. Given that CMOs often collaborate with multiple clients, the potential for unintentional sharing or theft of confidential information remains a critical issue. Such incidents could lead to legal disputes and damage the reputation of contract manufacturers, ultimately hindering market growth.
To maintain a competitive advantage, it is essential for contract manufacturers to continuously adapt to emerging technologies and industry advancements. Staying at the forefront of innovations in biopharmaceutical manufacturing will be crucial as CMOs navigate this dynamic and rapidly evolving sector.
As the industry progresses, stakeholders are encouraged to proactively address these challenges to ensure sustainable growth and the continued delivery of high-quality biopharmaceutical products to the global market.
“The increased usage of biologics in a variety of therapeutic areas, a growing need for customized treatment, and the emergence of new manufacturing technologies that allow for more efficient and cost-effective biopharmaceutical production drive the market’s progress,” says an analyst at FMI.
Key Takeaways from the Biopharmaceutical Contract Manufacturing Market:
- The global biopharmaceutical contract manufacturing market is estimated to register a CAGR of 8.8% through 2034.
- The market is expected to reach a valuation of USD 25.1 billion by 2034.
- The mammalian-based segment is anticipated to dominate the market, accounting for 73.0% of the market share in 2024.
- With a 51.0% market share, the monoclonal antibodies segment is estimated to dominate the market in 2024.
Explore the Full Market Scope: Find the Complete Biopharmaceutical Contract Manufacturing Market Report Here
Competitive Landscape:
The biopharmaceutical contract manufacturing industry is getting more competitive as the demand for biologics and biosimilars rises. Companies have a solid reputation for offering high-quality contract manufacturing services to the biopharmaceutical industry. However, some smaller market participants are gaining traction and competing with the larger corporations by providing specialized services and innovative technologies.
Some prominent companies in the market include Catalent Inc., Lonza Group Ag, Patheon N.V. (Thermo Fisher Scientific Inc.), Abzena Plc., Sandoz International GmbH (Novartis AG), Fujifilm Diosynth Biotechnologies (FUJIFILM Holdings), Baxter Pharmaceutical Solutions LLC (Baxter Inc.), AbbVie Contract Manufacturing (AbbVie Inc.), Samsung Biologics Co. Ltd., ProBioGen AG, Pfizer Centre Source Ltd.
Key Market Segments:
By Platform Type:
- Mammalian Based
- Microbial Based
By Product Type:
- Monoclonal Antibodies
- Recombinant Protein
- Vaccine
- Insulin
- Growth factor
- Interferons
- Others
By Application Type:
- Clinical
- Commercial
By Therapeutic Area Type:
- Autoimmune Diseases
- Oncology
- Metabolic Diseases
- Ophthalmology
- Cardiovascular Diseases
- Infectious Diseases
- Neurology
- Respiratory Disorders
- Others
By Region:
- North America
- Latin America
- East Asia
- South Asia
- Europe
- Oceania
- MEA
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube